Summary#
Senate Resolution No. 703 suspends parts of a Texas Senate rule so the conference committee on S.B. 2308 can consider specified changes outside its usual limits. The resolution does not itself change health law or create the proposed ibogaine trial program; its stated goal is to let the committee consider a revised bill. The Senate adopted it on May 31, 2025, by a 31–0 vote.
The resolution permits the committee to consider changes that would:
- Replace a proposed grant program and rulemaking duty with a process for consortia to seek funding through proposals to the Health and Human Services Commission (HHSC).
- Let HHSC select a consortium in its sole discretion, then require HHSC to contract with its lead university or other higher-education institution. The contract would set goals, budget, timeline, collaborating entities, and the state’s share of revenue.
- Require matching funds from non-state sources before HHSC could disburse state funds, and allow payments in stages tied to completed objectives and documented spending.
- Require the selected consortium to submit quarterly progress and financial reports; HHSC would report trial progress to the legislature each year.
- Set aside at least 20% of revenue from intellectual property and other commercial rights arising from the trials for the state. Of state revenue received, 25% could be appropriated only for programs assisting Texas veterans.
- Limit trial sites to hospitals and higher-education institutions, and require a consortium member or its lead institution to submit an investigational new drug application and seek FDA breakthrough therapy designation.
These are changes the resolution allows the conference committee to consider. It does not establish that the committee adopted them into S.B. 2308.
What it means for you#
- General public: The resolution itself does not change treatment access, drug approval, or anyone’s legal rights. It changes what the S.B. 2308 conference committee is allowed to consider.
- Potential consortium members: The permitted proposal would require a drug developer, a higher-education institution, and a hospital in each consortium. The lead institution would submit the proposal and represent the consortium.
- Researchers, hospitals, and drug developers: If the proposed provisions became law, a selected consortium would have to seek FDA authorization before trials, and only a hospital or higher-education institution could be a trial site.
- Taxpayers: The resolution itself does not authorize trial spending. The changes it permits would require HHSC to fund a selected consortium under a contract, subject to verified matching funds from non-state sources.
- People seeking ibogaine treatment: The resolution does not approve ibogaine or guarantee trials, FDA approval, insurance coverage, or treatment access.
Money#
The resolution has no cost estimate and does not itself authorize spending; the changes it permits would require HHSC to provide funding under a contract.
- The permitted contract would include a proposed budget, but the resolution sets no funding amount.
- HHSC could not disburse state funds until it verified non-state matching funds. Payments could be made in stages based on objectives and documented spending.
- The proposed provisions would allocate at least 20% of revenue from covered intellectual property and other commercial rights to the state. They do not guarantee that revenue will arise.
- The resolution contains no estimate of staffing, trial, or administrative costs.
What is unclear#
- The supplied material does not show the final text of S.B. 2308 or whether the conference committee adopted these permitted changes. I cannot verify the resulting law against current Texas law.
- The resolution does not require the committee to use every change it permits.
- The permitted text leaves the amount of state funding, the matching-fund amount, and the contract’s specific terms unset.
- It does not specify how HHSC would choose among proposals beyond giving the agency sole discretion; the proposed selection committee is removed.
- The supplied material does not explain what trial oversight or site-safety requirements would apply under the final bill.
Case for#
- A possible argument for the resolution is that it lets the conference committee consider a more detailed way to fund ibogaine trials, rather than the grant program described in the earlier text.
- The permitted changes would require non-state matching funds before state money is paid and allow payments to depend on completed objectives and documented spending.
- The proposed reporting and state revenue share could give the state information about progress and a return if commercial revenue results.
- Requiring a consortium to include a drug developer, a higher-education institution, and a hospital could bring different kinds of expertise into the trial effort.
Case against#
- One concern is that the permitted text gives HHSC sole discretion to select a consortium and removes the proposed selection committee, without setting out detailed selection criteria.
- The proposed contract and reporting rules do not, by themselves, specify trial oversight, safety standards, or how the state would check that trial sites meet them.
- Requiring matching funds may limit which consortia can proceed, while the resolution does not set a funding amount or explain how much state money could be committed.
- The resolution allows major policy changes to be considered in a conference committee, but the supplied material does not show which changes became part of the final bill.